Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
20. November 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
15. November 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
17. August 2024 11:27 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
16. August 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
25. Juli 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment
15. Juli 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
28. Mai 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
20. Mai 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
16. Mai 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
01. April 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream